Operating Lease, Right-of-Use Asset in USD of Ambrx Biopharma Cayman, Inc. from Q4 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Operating Lease, Right-of-Use Asset history and change rate from Q4 2020 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Jun 2023 was $10,044,000.000, a 15.3% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2023 $10,044,000 -$1,816,000 -15.3% 30 Jun 2023 10-Q 09 Aug 2023
Q1 2023 $10,511,000 31 Mar 2023 10-Q 11 May 2023
Q4 2022 $10,968,000 -$1,769,000 -13.9% 31 Dec 2022 10-Q 09 Aug 2023
Q2 2022 $11,860,000 30 Jun 2022 6-K 29 Aug 2022
Q4 2021 $12,737,000 +$10,096,000 +3.8% 31 Dec 2021 10-K 30 Mar 2023
Q4 2020 $2,641,000 31 Dec 2020 20-F 26 Apr 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.